0001193125-22-178866.txt : 20220622 0001193125-22-178866.hdr.sgml : 20220622 20220622170755 ACCESSION NUMBER: 0001193125-22-178866 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220622 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220622 DATE AS OF CHANGE: 20220622 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sierra Oncology, Inc. CENTRAL INDEX KEY: 0001290149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37490 FILM NUMBER: 221032792 BUSINESS ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 BUSINESS PHONE: (605) 376-8679 MAIL ADDRESS: STREET 1: 1820 GATEWAY DRIVE STREET 2: SUITE 110 CITY: SAN MATEO STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: ProNAi Therapeutics Inc DATE OF NAME CHANGE: 20040513 8-K 1 d303581d8k.htm 8-K 8-K
false 0001290149 0001290149 2022-06-22 2022-06-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 22, 2022

 

 

SIERRA ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-37490   20-0138994

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1820 Gateway Drive, Suite 110

San Mateo, California

   94404
(Address of principal executive offices)   (Zip Code)

(650) 376-8679

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value   SRRA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

Supplemental Disclosures

As previously disclosed, on April 12, 2022, Sierra Oncology, Inc. (which we refer to as the “Company” or “Sierra Oncology”) entered into an Agreement and Plan of Merger (which we refer to as the “Merger Agreement”) with GlaxoSmithKline plc (which we refer to as “GSK”) and Orikum Acquisition Inc. (which we refer to as “Acquisition Sub”). We refer to the merger of Acquisition Sub (an indirect wholly owned subsidiary of GSK) with and into Sierra Oncology as the “merger.” On May 16, 2022, Sierra Oncology filed a definitive proxy statement (which we refer to as the “proxy statement”), as such may be supplemented from time to time, with the Securities and Exchange Commission (which we refer to as the “SEC”) with respect to the special meeting of Sierra Oncology’s stockholders (which we refer to as the “special meeting”) scheduled to be held on June 29, 2022, at 10:10 a.m., Pacific time. Additional information about how to attend the special meeting is contained in the proxy statement. Capitalized terms used in this supplement that are not defined herein have the meaning given to them in the proxy statement.

Explanatory Note

In connection with the Merger Agreement, seven complaints have been filed in United States District Courts. Three complaints have been filed in the United States District Court for the Southern District of New York and are captioned O’Dell v. Sierra Oncology, Inc., et al., 1:22-cv-03647 (filed May 5, 2022); Raul v. Sierra Oncology, Inc., et al., 1:22-cv-04468 (filed May 31, 2022); and Wheeler v. Sierra Oncology, Inc., et al., 1:22-cv-04791 (filed June 8, 2022). Three complaints have been filed in the United States District Court for the Eastern District of New York and are captioned Bailey v. Sierra Oncology, Inc., et al., 1:22-cv-02785 (filed May 12, 2022); Baker v. Sierra Oncology, Inc., et al., 1:22-cv-02794 (filed May 12, 2022); and Whitfield v. Sierra Oncology, Inc., et al., 1:22-cv-02906 (filed May 18, 2022). One complaint has been filed in the United States District Court for the Northern District of California and is captioned Arrow v. Sierra Oncology, Inc., et al., 3:22-cv-02742 (filed May 9, 2022). The foregoing complaints are referred to as the “Merger Actions.” The Merger Actions, which name as defendants Sierra Oncology and members of the Sierra Oncology Board, allege that Sierra Oncology’s proxy statement is materially incomplete and misleading in violation of Sections 14(a) and 20(a) of the Exchange Act. The Merger Actions seek, among other relief, corrective disclosures, an injunction of the merger, rescission or rescissory damages (if the merger is consummated), damages, and attorneys’ fees.

In addition, Sierra Oncology has received a total of five demand letters from purported stockholders of the Company (which we refer to as the “Demand Letters”), alleging that the proxy statement contained disclosure deficiencies and/or incomplete information in connection with the merger.

Sierra Oncology believes that the disclosures set forth in the proxy statement comply fully with all applicable law and that the allegations contained in the Merger Actions and Demand Letters are without merit. However, in order to moot the purported stockholders’ unmeritorious disclosure claims, alleviate the costs, risks and uncertainties inherent in litigation, and provide additional information to its stockholders, Sierra Oncology has determined to voluntarily supplement the proxy statement with certain supplemental disclosures set forth below (which we refer to as the “Supplemental Disclosures”). Nothing in the Supplemental Disclosures shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the disclosures in this amendment. To the contrary, Sierra Oncology specifically denies all allegations by the purported stockholders in the Merger Actions and Demand Letters that any additional disclosure was or is required or material. The Supplemental Disclosures will not affect the timing of the special meeting.

All page references used herein refer to pages in the proxy statement before any additions or deletions resulting from the Supplemental Disclosures, and certain terms used below, unless otherwise defined, have the meanings set forth in the proxy statement. The Supplemental Disclosures should be read in conjunction with the proxy statement, which should be read in its entirety. The Supplemental Disclosures are identified below by bold, underlined text.

Stricken-through text shows text being deleted from a referenced disclosure in the proxy statement. Except as specifically noted herein, the information set forth in the proxy statement remains unchanged.

Supplemental Disclosures to the Proxy Statement

The section of the proxy statement entitled “Background of the Merger” is hereby supplemented as follows:

The forty ninth paragraph under the heading “Background of the Merger” on page 40 of the proxy statement is hereby supplemented to read as follows:

Also on April 4, 2022, Wilson Sonsini delivered an initial draft of the definitive agreement to Cleary Gottlieb Steen & Hamilton LLP, GSK’s outside counsel (which we refer to as “Cleary Gottlieb”) in connection with the merger. Between April 4, 2022 and April 12, 2022, representatives of Sierra Oncology and GSK and their respective legal advisors negotiated the terms of the merger agreement. Key terms of the merger agreement negotiated between the parties included (1) the structure of the acquisition, (2) the terms of the “no-shop” restrictions and the circumstances in which the Sierra Oncology Board could change its recommendation to its stockholders or negotiate or accept an alternative acquisition transaction, including the circumstances in which the merger agreement could be terminated; (3) the amount of the termination fee and the circumstances in which it would be payable; (4) the definition of “Material Adverse Effect” with respect to Sierra Oncology; (5) the conditions to each party’s obligation to complete the merger; (6) the parties’ commitments in connection with obtaining required regulatory approvals; (7) the interim operating covenants applicable to Sierra Oncology prior to the closing of the merger and related exceptions for matters such as employee hiring and compensation and entry into material contracts or transactions by Sierra Oncology; and (8) Sierra Oncology’s other representations, warranties and covenants in the merger agreement. Representatives of GSK also discussed with representatives of Sierra Oncology the possibility of entering into retention agreements with certain members of Sierra Oncology management following the completion of the merger to facilitate GSK’s integration and transition efforts with respect to Sierra Oncology’s business and product candidates, and potential related compensation arrangements. The Sierra Oncology Board was kept apprised of these discussions. None of the initial GSK proposal, the revised GSK proposal or the last GSK proposal included provisions regarding retention or compensation agreements with members of Sierra Oncology management, Sierra Oncology directors or their respective affiliates, including with respect to equity participation in GSK or the surviving corporation. GSK declined to enter into any retention or compensation agreements with members of Sierra Oncology management prior to the execution of the merger agreement.

The section of the proxy statement entitled “Opinion of Lazard Frères & Co. LLC — Financial Analyses — Discounted Cash Flow Analysis” is hereby supplemented as follows:

The third paragraph under the heading “Discounted Cash Flow Analysis” on page 49 of the proxy statement is hereby supplemented to read as follows:

For purposes of this analysis, Lazard Frères calculated a range of enterprise values for Sierra Oncology by discounting to present value, utilizing discount rates ranging from 10.0% to 12.0%, chosen by Lazard Frères based upon its analysis of the weighted average cost of capital of Sierra Oncology and using the mid-year convention, (i) the estimated probability-adjusted, after-tax unlevered free cash flows to be generated by Sierra Oncology from March 31, 2022 through the end of terminal year of 2040; and (ii) a range of terminal values for Sierra Oncology. Using the mid-year convention, the discount rates applicable to Sierra Oncology were derived (1) using market data as of April 11, 2022 and (2) from an analysis of the weighted average cost of capital of the selected comparable companies, which Lazard performed utilizing the capital asset pricing model with inputs Lazard determined were relevant based on publicly available data and Lazard’s professional judgment.

The fourth paragraph under the heading “Discounted Cash Flow Analysis” on page 49 of the proxy statement is hereby supplemented to read as follows:

The terminal values were derived by applying a negative terminal growth rate range of (50%) – (30%) to the estimated unlevered free cash flow for the terminal year to be generated by Sierra Oncology. The negative terminal growth rates used by Lazard Frères were estimated by Lazard Frères based on its professional judgment and experience concerning the future growth rate of Sierra Oncology and given the stage of the business life cycle at that time, taking into account the Unaudited Prospective Financial Information and publicly available data.

The section of the proxy statement entitled “Opinion of Lazard Frères & Co. LLC — Financial Analyses — Selected Public Companies Analysis” is hereby supplemented as follows:

The list on page 50 of the proxy statement under the language “The companies in the biotechnology industry selected by Lazard Frères for this analysis were as follows…” is hereby amended and restated as follows:

 

Company    Enterprise Value /
Probability-Adjusted
FY+5 Revenue		  

Blueprint Medicines Corporation

      2.8x  

Iovance Biotherapeutics, Inc.

      1.7x  

ImmunoGen, Inc.

      1.0x  

ADC Therapeutics SA

      1.5x  

Karyopharm Therapeutics Inc.

      2.4x  

Macrogenics, Inc.

      0.7x  

CTI Biopharma Corp.

      1.5x  

The section of the proxy statement entitled “Opinion of Lazard Frères & Co. LLC — Financial Analyses — Selected Precedent Transactions Analysis” is hereby supplemented as follows:

The table on page 51 of the proxy statement under the second paragraph under the heading “Selected Precedent Transactions Analysis” is hereby amended and restated as follows:

 

Announcement

Date

   

Acquiror

   

Target

    TV / Probability-
Adjusted
FY+5 Revenue		  
06/02/21    MorphoSys AG    Constellation Pharmaceuticals, Inc.      1.2x  
03/04/21    Amgen Inc.    Five Prime Therapeutics, Inc.      3.3x  
05/04/20    A. Menarini—Industrie Farmaceutiche Riunite—S.R.L.    Stemline Therapeutics, Inc.      1.6x  
05/10/18    Eli Lilly and Company    ARMO BioSciences, Inc.      2.7x  
01/31/18    Seattle Genetics, Inc.    Cascadian Therapeutics, Inc.      1.1x  

The section of the proxy statement entitled “Opinion of Lazard Frères & Co. LLC — Financial Analyses — Other Analyses — Premia Paid Analysis” is hereby supplemented as follows:

The first paragraph under the heading “Premia Paid Analysis” on page 51 of the proxy statement is hereby supplemented as follows:

Using information from public filings and other publicly available information, Lazard Frères analyzed the premia paid for acquisitions of publicly-traded companies in the biotechnology industry by strategic buyers with transaction equity values implied for the target company in the transaction based on the consideration payable at the closing of the 23 selected transactions (excluding contingent value rights) ranging between $1 billion and $4 billion that have been announced since January 1, 2018. These transactions are listed below. For each of the precedent transactions, Lazard Frères calculated the implied premia as a percentage based on the amount by which the per share consideration in each transaction exceeded the target company’s (i) closing share price on the last trading day upon which shares of Sierra Oncology traded on an unaffected basis, (ii) 30-day volume weighted average price based on trading days (“VWAP”) and (iii) 52-week high share price based on intraday prices.

 

Announcement
Date		   

Acquiror

   

Target

01/19/22    UCB S.A.    Zogenix, Inc.
11/18/21    Novo Nordisk A/S    Dicerna Pharmaceuticals, Inc.
09/08/21    Sanofi SA    Kadmon Holdings, Inc.
08/23/21    Pfizer Inc.    Trillium Therapeutics Inc.
08/03/21    Sanofi SA    Translate Bio, Inc.
06/02/21    MorphoSys AG    Constellation Pharmaceuticals, Inc.
03/04/21    Amgen Inc.    Five Prime Therapeutics, Inc.
02/25/21    Merck & Co., Inc.    Pandion Therapeutics, Inc.
02/01/21    Horizon Therapeutics Public Limited Company    Viela Bio, Inc.
11/05/20    Novo Nordisk A/S    Emisphere Technologies, Inc.
10/05/20    BridgeBio Pharma, Inc.    Eidos Therapeutics, Inc.
08/31/20    Ionis Pharmaceuticals, Inc.    Akcea Therapeutics, Inc.
08/31/20    Nestle S.A.    Aimmune Therapeutics, Inc.
08/17/20    Sanofi SA    Principia Biopharma Inc.
05/05/20    Alexion Pharmaceuticals, Inc.    Portola Pharmaceuticals, Inc.
01/10/20    Eli Lilly and Company    Dermira, Inc.
12/09/19    Sanofi SA    Synthorx, Inc.
12/09/19    Merck & Co., Inc.    ArQule, Inc.
12/02/19    Astellas Pharma Inc.    Audentes Therapeutics, Inc.
10/10/19    UCB S.A.    Ra Pharmaceuticals, Inc.
09/16/19    H. Lundbeck A/S    Alder BioPharmaceuticals, Inc.
10/18/18    Novartis AG    Endocyte, Inc.
05/10/18    Eli Lilly and Company    ARMO BioSciences, Inc.

The section of the proxy statement entitled “Opinion of Lazard Frères & Co. LLC — Financial Analyses — Miscellaneous” is hereby supplemented as follows:

The second paragraph under the heading “Miscellaneous” on page 52 of the proxy statement is hereby supplemented to read as follows:

In addition, Sierra Oncology has agreed to reimburse Lazard for its reasonable out-of-pocket expenses incurred in connection with its engagement, including reasonable fees of counsel, and will indemnify Lazard and certain related persons against certain liabilities arising out of Lazard’s engagement. As part of the Sierra Oncology Board’s evaluation of strategic alternatives, Lazard had previously and from time-to-time reviewed with the Sierra Oncology Board its preliminary market and valuation perspectives with respect to Sierra Oncology and the biopharmaceutical industry generally, as well as potential counterparties for a partnership or other strategic transaction involving Sierra Oncology. Lazard did not receive compensation for such services. Lazard has in the two years prior to the delivery of Lazard Frères’ opinion on April 12, 2022 provided certain financial advisory services to GSK and certain of its affiliates, including advising GSK in connection with investor analysis, for which Lazard has received and expects to receive compensation in an amount less than $150,000 in the aggregate. Lazard, as part of its investment banking business, is continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements, leveraged buyouts, and valuations for estate, corporate and other purposes. In addition, in the ordinary course, Lazard and its affiliates and employees may trade securities of Sierra Oncology, GSK and certain of their affiliates for their own accounts and for the accounts of their customers, may at any time

hold a long or short position in such securities, and may also trade and hold securities on behalf of Sierra Oncology, GSK and certain of their respective affiliates. The issuance of Lazard Frères’ opinion was approved by the opinion committee of Lazard Frères.

Forward Looking Statements

This communication contains certain statements that constitute forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the satisfaction of conditions to the closing of the proposed acquisition of the Company by GSK and the expected occurrence and timing of the consummation of the proposed acquisition, as well as other statements that are not historical fact. These forward-looking statements are based on currently available information, as well as the Company’s views and assumptions regarding future events as of the time such statements are being made. Such forward looking statements are subject to inherent risks and uncertainties. Accordingly, actual future events or results may differ from those expressed or implied in such forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk that the conditions to the closing of the proposed acquisition are not satisfied, including the risk that the required approval of the Company’s stockholders is not obtained; potential litigation relating to the proposed acquisition; uncertainties as to the timing of the consummation of the proposed acquisition and the ability of each party to consummate the acquisition; the failure to realize anticipated benefits of the proposed acquisition when expected or at all; potential adverse reactions or changes to business relationships resulting from the proposed acquisition, including the effect of the announcement on the ability of the Company to retain and hire key personnel; risks that the proposed acquisition disrupts the current plans and operations of the Company; and other risks and uncertainties described in cautionary statements contained in the Company’s periodic reports filed with the SEC including the statements set forth under “Risk Factors” set forth in the Company’s most recent annual report on Form 10-K and the proxy statement filed by the Company with the SEC on May 16, 2022 in connection with the proposed acquisition. While the Company may elect to update any such forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if our expectations change, except as required by law.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SIERRA ONCOLOGY, INC.
Date: June 22, 2022     By:  

/s/ Christina Thomson

      Christina Thomson
      General Counsel, Chief Compliance Officer and Secretary
 EX-101.SCH 2 srra-20220622.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 srra-20220622_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 srra-20220622_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Document and Entity Information
Jun. 22, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001290149
Document Type 8-K
Document Period End Date Jun. 22, 2022
Entity Registrant Name SIERRA ONCOLOGY, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-37490
Entity Tax Identification Number 20-0138994
Entity Address, Address Line One 1820 Gateway Drive
Entity Address, Address Line Two Suite 110
Entity Address, City or Town San Mateo
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (650)
Local Phone Number 376-8679
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol SRRA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d303581d8k_htm.xml IDEA: XBRL DOCUMENT 0001290149 2022-06-22 2022-06-22 false 0001290149 8-K 2022-06-22 SIERRA ONCOLOGY, INC. DE 001-37490 20-0138994 1820 Gateway Drive Suite 110 San Mateo CA 94404 (650) 376-8679 false false false false Common Stock, $0.001 par value SRRA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d303581d8k.htm srra-20220622.xsd srra-20220622_lab.xml srra-20220622_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d303581d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d303581d8k.htm" ] }, "labelLink": { "local": [ "srra-20220622_lab.xml" ] }, "presentationLink": { "local": [ "srra-20220622_pre.xml" ] }, "schema": { "local": [ "srra-20220622.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "srra", "nsuri": "http://sierraoncology.com/20220622", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d303581d8k.htm", "contextRef": "duration_2022-06-22_to_2022-06-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d303581d8k.htm", "contextRef": "duration_2022-06-22_to_2022-06-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sierraoncology.com//20220622/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001193125-22-178866-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-178866-xbrl.zip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end